

Sameer A Parikh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3938131/publications.pdf>

Version: 2024-02-01

164
papers

4,883
citations

136950

32
h-index

106344

65
g-index

164
all docs

164
docs citations

164
times ranked

5362
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
2	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
3	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	1.4	335
4	Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 484-492.	3.0	244
5	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
6	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	2.5	187
7	A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. <i>Cancer</i> , 2017, 123, 3229-3240.	4.1	155
8	How we treat Richter syndrome. <i>Blood</i> , 2014, 123, 1647-1657.	1.4	145
9	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
10	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017, 58, 1630-1639.	1.3	102
11	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
12	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	1.4	83
13	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015, 121, 2883-2891.	4.1	77
14	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015, 100, 1180-1188.	3.5	70
15	Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 334-338.	4.1	69
16	Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 1752-1760.	1.4	67
17	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	2.5	66
18	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020, 105, 765-773.	3.5	64

#	ARTICLE	IF	CITATIONS
19	Chronic lymphocytic leukemia treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018, 8, 93.	6.2	63
20	Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. <i>Haematologica</i> , 2014, 99, 140-147.	3.5	60
21	Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 458-465.	3.5	60
22	Prognostic factors and risk stratification in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 233-240.	2.2	59
23	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). <i>American Journal of Surgical Pathology</i> , 2018, 42, 843-854.	3.7	54
24	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in Multiple myeloma. <i>Blood</i> , 2022, 139, 3708-3721.	1.4	53
25	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016, 128, 2093-2095.	1.4	52
26	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021, 29, 1529-1540.	8.2	43
27	NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1335-1338.	1.1	42
28	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	1.3	42
29	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 610-619.	4.1	41
30	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	2.5	41
31	Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 294-299.	2.3	38
32	A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 29-38.	2.3	38
33	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018, 183, 421-427.	2.5	37
34	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020, 9, 3390-3399.	2.8	36
35	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017, 58, 1376-1383.	1.3	33
36	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021, 100, 143-155.	1.8	32

#	ARTICLE	IF	CITATIONS
37	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	17.0	31
38	Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 1973-1976.	1.3	28
39	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
40	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). <i>Vaccine</i> , 2021, 39, 1122-1130.	3.8	26
41	CLL update 2022: A continuing evolution in care. <i>Blood Reviews</i> , 2022, 54, 100930.	5.7	24
42	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 967-974.	4.1	23
43	<sc>CD</sc>49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 178, 99-105.	2.5	23
44	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	7.2	21
45	Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2019, 33, 638-652.	7.2	21
46	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021, 35, 239-244.	7.2	21
47	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021, 138, 149-159.	1.4	20
48	<i>IGH</i> translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019, 94, 338-345.	4.1	19
49	Comparison between the CLLâ€PI and the <sc>B</sc>â€rno prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37.	4.1	18
50	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
51	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. <i>Blood</i> , 2015, 126, 2935-2935.	1.4	18
52	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
53	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600.	1.3	17
54	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020, 95, 906-917.	4.1	17

#	ARTICLE	IF	CITATIONS
55	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	1.4	17
56	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020, 105, 2675-2678.	3.5	17
57	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e407-e414.	4.6	16
58	Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. <i>Blood Advances</i> , 2019, 3, 1298-1302.	5.2	16
59	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	1.4	16
60	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018, 103, e237-e240.	3.5	15
61	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	4.1	15
62	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	3.7	15
63	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. <i>Blood Advances</i> , 2020, 4, 4508-4511.	5.2	15
64	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	3.5	15
65	Single-Antibody Evaluation of T-Cell Receptor β Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2021, 156, 139-148.	0.7	15
66	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	1.3	15
67	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021, 11, 86.	6.2	14
68	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	3.4	14
69	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017, 92, 1362-1369.	4.1	13
70	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2022, 97, 90-98.	4.1	13
71	Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 720-9.	0.3	13
72	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 865-865.	1.4	12

#	ARTICLE	IF	CITATIONS
73	GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. <i>Leukemia</i> , 2022, 36, 1635-1645.	7.2	12
74	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e22-e25.	3.5	11
75	Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 337-349.	2.2	11
76	<i>Cryptococcus neoformans</i> infections in patients with lymphoproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019, 60, 920-926.	1.3	11
77	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	7.2	10
78	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <i>Leukemia and Lymphoma</i> , 2019, 60, 559-561.	1.3	9
79	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60.	4.1	9
80	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	1.4	9
81	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	6.2	9
82	Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 199, 239-244.	2.5	9
83	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	7.2	8
84	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. <i>Blood</i> , 2015, 126, 717-717.	1.4	8
85	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	1.4	8
86	Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. <i>Future Oncology</i> , 2014, 10, 2201-2212.	2.4	7
87	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 47.	6.2	7
88	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , 2019, 134, 1754-1754.	1.4	7
89	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 50-51.	1.4	7
90	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140.	6.2	6

#	ARTICLE	IF	CITATIONS
91	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated CarTs. Blood, 2019, 134, 3868-3868.	1.4	6
92	Calm before the Storm. New England Journal of Medicine, 2022, 386, 479-485.	27.0	6
93	Early intervention in asymptomatic chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2021, 19, 92-103.	0.3	6
94	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. Leukemia and Lymphoma, 2020, 61, 1752-1755.	1.3	5
95	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2950-2950.	1.4	5
96	Oral capecitabine to prevent recurrent cutaneous squamous cell carcinoma in a lung transplant recipient. International Journal of Dermatology, 2015, 54, e358-60.	1.0	4
97	Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leukemia and Lymphoma, 2018, 59, 2287-2296.	1.3	4
98	Predicting Time to First Treatment in Chronic Lymphocytic Leukemia Using Machine Learning Survival and Classification Methods. , 2018, , .		4
99	Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications. Leukemia and Lymphoma, 2020, 61, 1037-1051.	1.3	4
100	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2020, 83, 1581-1589.	1.2	4
101	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. Leukemia, 2020, 34, 1979-1983.	7.2	4
102	Chronic lymphocytic leukemia B-cell-derived TNF α impairs bone marrow myelopoiesis. Science, 2021, 24, 101994.	4.1	4
103	A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2020, 136, 51-52.	1.4	4
104	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer Journal, 2022, 12, 30.	6.2	4
105	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2019, 134, 4306-4306.	1.4	3
106	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. Blood, 2019, 134, 3050-3050.	1.4	3
107	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. Blood, 2015, 126, 1014-1014.	1.4	3
108	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. Blood, 2015, 126, 4169-4169.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017, 130, 831-831.	1.4	3
110	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021, 138, 906-906.	1.4	3
111	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	1.4	3
112	A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
113	Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1289-1301.	1.3	2
114	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. <i>Blood</i> , 2018, 132, 4433-4433.	1.4	2
115	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. <i>Blood</i> , 2019, 134, 53-53.	1.4	2
116	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018, 132, 586-586.	1.4	2
117	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2022, 40, 302-306.	1.7	2
118	Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma. <i>Human Pathology</i> , 2022, 125, 2-10.	2.0	2
119	B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	2
120	Upregulation of AXL and β -catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. <i>Blood Cancer Journal</i> , 2021, 11, 37.	6.2	1
121	The prognostic significance of $\langle scp \rangle \text{del}6q23 \langle /scp \rangle$ in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E203-E206.	4.1	1
122	Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>Blood</i> , 2018, 132, 728-728.	1.4	1
123	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 679-679.	1.4	1
124	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	1.4	1
125	Central Nervous System Involvement By Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2919-2919.	1.4	1
126	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016, 128, 2020-2020.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Novel Mutations in NOTCH and Altered Wnt/ β 2-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4103-4103.	1.4	1
128	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016, 128, 5592-5592.	1.4	1
129	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
130	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	1.4	1
131	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
132	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 16-17.	1.4	1
133	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
134	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	7.2	1
135	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 111, 32-40.	0.4	1
136	Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.4	0
137	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. <i>Journal of Hematopathology</i> , 2020, 13, 221-229.	0.4	0
138	Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 151-159.	4.1	0
139	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015, 126, 481-481.	1.4	0
140	National Epidemiology of Inpatient Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012. <i>Blood</i> , 2015, 126, 630-630.	1.4	0
141	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2926-2926.	1.4	0
142	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016, 128, 5585-5585.	1.4	0
143	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	1.4	0
144	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016, 128, 5575-5575.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016, 128, 3228-3228.	1.4	0
146	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018, 132, 3116-3116.	1.4	0
147	Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions. <i>Blood</i> , 2018, 132, 1865-1865.	1.4	0
148	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018, 132, 1857-1857.	1.4	0
149	Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment. <i>Blood</i> , 2018, 132, 3132-3132.	1.4	0
150	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	1.4	0
151	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018, 132, 5538-5538.	1.4	0
152	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019, 134, 3022-3022.	1.4	0
153	A Role for TNF- α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. <i>Blood</i> , 2019, 134, 4276-4276.	1.4	0
154	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 852-852.	1.4	0
155	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019, 134, 3037-3037.	1.4	0
156	Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2021, 138, 4677-4677.	1.4	0
157	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021, 138, 2777-2777.	1.4	0
158	B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2021, 138, 3313-3313.	1.4	0
159	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
160	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
161	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 10-12.	1.4	0
162	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020, 136, 28-29.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	1.4	0
164	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 1-1.	1.4	0